All CIRM Grants

Institution Researcher name Grant Type Grant Title Award Value
University of California, Los Angeles Donald Kohn Early Translational IV Beta-Globin Gene Correction of Sickle Cell Disease in Hematopoietic Stem Cells $1,652,076
University of California, San Francisco Holger Willenbring Early Translational III Generation of safe and therapeutically effective human induced hepatocyte-like cells $1,544,170
University of California, San Diego Alysson Muotri Early Translational IV A drug-screening platform for autism spectrum disorders using human astrocytes $1,656,456
Stanford University Joseph Wu Early Translational III Heart Repair with Human Tissue Engineered Myocardium $4,397,241
University of California, Los Angeles Leif Havton Early Translational II Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons $75,628
University of California, Los Angeles Noriyuki Kasahara Early Translational II Stem cell-based carriers for RCR vector delivery to glioblastoma $3,340,625
Stanford University Michele Calos Early Translational IV Engineered iPSC for therapy of limb girdle muscular dystrophy type 2B $1,876,253
Stanford University Jill Helms Early Translational I Enhancing healing via Wnt-protein mediated activation of endogenous stem cells $6,464,126
University of California, Los Angeles Sophie Deng Early Translational II Regeneration of Functional Human Corneal Epithelial Progenitor Cells $699,983
University of California, Los Angeles Zack Jerome Early Translational IV Stem Cell Programming With Chimeric Antigen Receptors to Eradicate HIV Infection $4,925,166
Human BioMolecular Research Institute John Cashman Early Translational IV Improving Existing Drugs for Long QT Syndrome type 3 (LQT3) by hiPSC Disease-in-Dish Model $6,361,369
Children's Hospital of Orange County Philip Schwartz Early Translational III Immune-Matched Neural Stem Cell Transplantation for Pediatric Neurodegenerative Disease $4,272,774
Cedars-Sinai Medical Center Dan Gazit Early Translational IV Gene Targeting to Endogenous Stem Cells for Segmental Bone Fracture Healing $5,180,674
Sanford-Burnham Medical Research Institute Stuart Lipton Early Translational IV Programming Human ESC-derived Neural Stem Cells with MEF2C for Transplantation in Stroke $885,000
University of California, San Diego Eugene Yeo Early Translational III Molecules to Correct Aberrant RNA Signature in Human Diseased Neurons $1,532,323
Numerate, Inc. John Griffin Early Translational IV Use of human iPSC-derived neurons from Huntington’s Disease patients to develop novel, disease-modifying small molecule structural corrector drug candidates targeting the unique, neurotoxic conformation of mutant huntingtin $520,015
Stanford University Bertha Chen Early Translational III Autologous iPSC Therapy for Urinary Incontinence $5,025,428
University of California, Los Angeles Robert Reiter Early Translational IV Clinical Development of an N-cadherin Antibody to Target Cancer Stem Cells $4,075,668
University of California, Los Angeles Gerald Lipshutz Early Translational IV Gene therapy-corrected autologous hepatocyte-like cells from induced pluripotent stem cells for the treatment of pediatric single enzyme disorders $1,801,629
Scripps Research Institute Peter Schultz Early Translational III Targeting Stem Cells to Enhance Remyelination in the Treatment of Multiple Sclerosis $2,623,242
University of California, San Diego Mark Tuszynski Early Translational III Functional Neural Relay Formation by Human Neural Stem Cell Grafting in Spinal Cord Injury $4,600,447
University of California, Irvine Magdalene Seiler Early Translational IV Restoring vision by sheet transplants of retinal progenitors and retinal pigment epithelium (RPE) derived from human embryonic stem cells (hESCs) $3,998,948
University of California, San Francisco Markus Muschen Early Translational II Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication $2,756,536
University of California, Irvine Brian Cummings Early Translational II Neural restricted, FAC-sorted, human neural stem cells to treat traumatic brain injury $1,517,767
University of California, Davis Kyriacos Athanasiou Early Translational III Tissue engineered cartilage from autologous, dermis-isolated, adult, stem (DIAS) cells $1,735,703
Gladstone Institutes Deepak Srivastava Early Translational III Direct Cardiac Reprogramming for Heart Regeneration $6,319,110
Gladstone Institutes Steven Finkbeiner Early Translational IV Development of Novel Autophagy Inducers to Block the Progression of and Treat Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Diseases $2,278,080
City of Hope Stephen Forman Early Translational III Targeting glioma cancer stem cells with receptor-engineered self-renewing memory T cells $5,217,004
University of California, Irvine Craig Walsh Early Translational III Multiple Sclerosis therapy: Human Pluripotent Stem Cell-Derived Neural Progenitor Cells $4,590,219
Salk Institute for Biological Studies Juan Carlos Izpisua Belmonte Early Translational III Direct reprogramming towards vascular progenitors for the treatment of ischemia $2,340,000
City of Hope Yanhong Shi Early Translational II Developing a therapeutic candidate for Canavan disease using induced pluripotent stem cell $1,835,983
University of California, San Francisco Morton Cowan Early Translational III Gene Correction of Autologous Hematopoietic Stem Cells in Artemis Deficient SCID $3,931,662
Scripps Research Institute Peter Schultz Early Translational II Cartilage Regeneration by the Chondrogenic Small Molecule PRO1 during Osteoarthritis $6,047,249
Gladstone Institutes Warner Greene Early Translational I Maximizing the Safety of Induced Pluripotent Stem Cells as an Infusion Therapy: Limiting the Mutagenic Threat of Retroelement Retrotransposition during iPSC Generation, Expansion and Differentiation $1,324,011
University of California, San Diego Eric Adler Early Translational III Identification of Novel Therapeutics for Danon Disease Using an iPS Model of the Disease $1,701,575
iPierian, Inc. John Dimos Early Translational II New Drug Discovery for SMA using Patient-derived Induced Pluripotent Stem Cells $2,410,000
Jackson Laboratory West Pali Kaur Early Translational I Mouse Models for Stem Cell Therapeutic Development $3,759,134
University of Southern California Toshio Miki Early Translational III Generation of hepatic cell from placental stem cell for congenital metabolic disorders $1,750,375
University of California, Davis Roslyn Isseroff Early Translational II Bone Marrow Mesenchymal Stem Cells to Heal Chronic Diabetic Wounds $4,635,576
Parkinson's Institute J. William Langston Early Translational I Using patient-specific iPSC derived dopaminergic neurons to overcome a major bottleneck in Parkinson's disease research and drug discovery $3,698,646
University of California, San Francisco Arnold Kriegstein Early Translational III Human ES cell-derived MGE inhibitory interneuron transplantation for spinal cord injury $1,623,251
University of California, San Diego Lawrence Goldstein Early Translational III Identifying Drugs for Alzheimer's Disease with Human Neurons Made From Human IPS cells $1,774,420
University of California, San Francisco Arturo Alvarez-Buylla Early Translational II Inhibitory Nerve Cell Precursors: Dosing, Safety and Efficacy $1,564,016
University of California, Los Angeles Bruno Peault Early Translational II Harnessing native fat-residing stem cells for bone regeneration $5,359,076
University of California, Los Angeles Gabriel Travis Early Translational I Development of a Stem Cell-based Transplantation Strategy for Treating Age-related Macular Degeneration $5,487,136
Salk Institute for Biological Studies Inder Verma Early Translational IV Development of a cell and gene based therapy for hemophilia $2,298,634
Cedars-Sinai Medical Center Dan Gazit Early Translational II Systemic Adult Stem Cell Therapy for Osteoporosis-Related Vertebral Compression Fractures $1,927,698
Salk Institute for Biological Studies Inder Verma Early Translational I Curing Hematological Diseases $5,979,252
University of California, San Diego Yang Xu Early Translational III Human ES cell based therapy of heart failure without allogenic immune rejection $1,857,600
Stanford University Michele Calos Early Translational II Stem Cell Therapy for Duchenne Muscular Dystrophy $2,267,261
Sanford-Burnham Medical Research Institute Evan Snyder Early Translational I Developmental Candidates for Cell-Based Therapies for Parkinson's Disease (PD) $5,190,752
Buck Institute for Age Research Xianmin Zeng Early Translational II Banking transplant ready dopaminergic neurons using a scalable process $4,983,013
University of California, Irvine leif Havton Early Translational II Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons $1,538,467
University of California, Davis Alice Tarantal Early Translational I In Utero Model to Assess the Fate of Transplanted Human Cells for Translational Research and Pediatric Therapies $3,143,392
University of California, Davis Mark Zern Early Translational II Liver Cell Transplantation $4,215,748
Salk Institute for Biological Studies Fred Gage Early Translational II Crosstalk: Inflammation in Parkinson’s disease (PD) in a humanized in vitro model $2,472,839
BioTime, Inc. Michael West Early Translational I Addressing the Cell Purity and Identity Bottleneck Through Generation and Expansion of Clonal Human Embryonic Progenitor Cell Lines $4,721,706
University of California, Davis Jan Nolta Early Translational I Sustained siRNA production from human MSC to treat Huntingtons Disease and other neurodegenerative disorders $2,615,674
University of California, San Diego Catriona Jamieson Early Translational II Preclinical development of a pan Bcl2 inhibitor for cancer stem cell directed therapy $3,103,041
University of California, Irvine Frank LaFerla Early Translational I Neural Stem Cells as a Developmental Candidate to Treat Alzheimer Disease $3,599,997
Children's Hospital of Los Angeles Markus Muschen Early Translational II Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication $850,769
University of California, Irvine Leslie Thompson Early Translational II A hESc-based Development Candidate for Huntington's Disease $4,045,253
University of California, San Diego Yang Xu Early Translational I Developing induced pluripotent stem cells into human therapeutics and disease models $5,165,028
University of California, San Diego Alysson Muotri Early Translational II Developing a drug-screening system for Autism Spectrum Disorders using human neurons $1,376,198
Scripps Research Institute Jeanne Loring Early Translational I Ensuring the safety of cell therapy: a quality control pipeline for cell purification and validation $5,830,771
Salk Institute for Biological Studies David Schubert Early Translational III Stem cell based small molecule therapy for Alzheimer's disease $1,673,757
City of Hope David DiGiusto Early Translational II Development of RNA-based approaches to stem cell gene therapy for HIV $3,097,160
ViaCyte, Inc. Olivia Kelly Early Translational I Methods for detection and elimination of residual human embryonic stem cells in a differentiated cell product $5,405,397
University of California, Los Angeles Sophie Deng Early Translational II Regeneration of Functional Human Corneal Epithelial Progenitor Cells $1,524,947
Scripps Health Darryl D'Lima Early Translational I Stem Cell-Based Therapy for Cartilage Regeneration and Osteoarthritis $3,118,431
Stanford University Helen Blau Early Translational III Local Delivery of Rejuvenated Old Muscle Stem Cells to Increase Strength in Aged Patients $1,825,920
University of California, Irvine Henry Klassen Early Translational II Human retinal progenitor cells as candidate therapy for retinitis pigmentosa $1,803,768
Scripps Research Institute Martin Friedlander Early Translational I Autologous Retinal Pigmented Epithelial Cells Derived from Induced Pluripotent Stem Cells for the Treatment of Atrophic Age Related Macular Degeneration $5,866,528
University of California, Davis Walter Boyd Early Translational III Extracellular Matrix Bioscaffold Augmented with Human Stem Cells for Cardiovascular Repair $4,633,149